Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Macrophage CD5L is a target for cancer immunotherapy.
Sanchez-Moral L, Paul T, Martori C, Font-Díaz J, Sanjurjo L, Aran G, Téllez É, Blanco J, Carrillo J, Ito M, Tuttolomondo M, Ditzel HJ, Fumagalli C, Tapia G, Sidorova J, Masnou H, Fernández-Sanmartín MA, Lozano JJ, Vilaplana C, Rodriguez-Cortés A, Armengol C, Valledor AF, Kremer L, Sarrias MR. Sanchez-Moral L, et al. Among authors: ditzel hj. EBioMedicine. 2023 May;91:104555. doi: 10.1016/j.ebiom.2023.104555. Epub 2023 Apr 11. EBioMedicine. 2023. PMID: 37054630 Free PMC article.
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.
Bertran-Alamillo J, Giménez-Capitán A, Román R, Talbot S, Whiteley R, Floc'h N, Martínez-Pérez E, Martin MJ, Smith PD, Sullivan I, Terp MG, Saeh J, Marino-Buslje C, Fabbri G, Guo G, Xu M, Tornador C, Aguilar-Hernández A, Reguart N, Ditzel HJ, Martínez-Bueno A, Nabau-Moretó N, Gascó A, Rosell R, Pease JE, Polanska UM, Travers J, Urosevic J, Molina-Vila MA. Bertran-Alamillo J, et al. Among authors: ditzel hj. Mol Cancer. 2023 Jul 13;22(1):110. doi: 10.1186/s12943-023-01815-w. Mol Cancer. 2023. PMID: 37443114 Free PMC article.
Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Ormhøj M, et al. Among authors: ditzel hj. Clin Cancer Res. 2024 May 15;30(10):2286. doi: 10.1158/1078-0432.CCR-24-1059. Clin Cancer Res. 2024. PMID: 38745479 No abstract available.
Geriatric screening and frailty intervention in older patients with cancer.
Giger AW, Ditzel HM, Lund CM, Ewertz M, Ditzel HJ, Ørum M, Pfeiffer P, Jørgensen TL, Ryg J. Giger AW, et al. Among authors: ditzel hj. Ugeskr Laeger. 2024 Jan 22;186(4):V06230352. doi: 10.61409/V06230352. Ugeskr Laeger. 2024. PMID: 38305324 Free article. Review. Danish.
Age-related differences in cancer biology in older patients.
Gammelgaard OL, Guldberg P, Gjerstorff MF, Ditzel HJ. Gammelgaard OL, et al. Among authors: ditzel hj. Ugeskr Laeger. 2024 Jan 22;186(4):V06230375. doi: 10.61409/V06230375. Ugeskr Laeger. 2024. PMID: 38305317 Free article. Review. Danish.
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis.
Gammelgaard OL, Terp MG, Kirkin AF, Johansen S, Traynor S, Vever H, Guldberg P, Kodahl AR, Gjerstorff MF, Ditzel HJ. Gammelgaard OL, et al. Among authors: ditzel hj. Mol Cancer. 2024 Jan 6;23(1):6. doi: 10.1186/s12943-023-01914-8. Mol Cancer. 2024. PMID: 38184565 Free PMC article.
Effects of comprehensive geriatric assessment-guided interventions on physical performance and quality of life in older patients with advanced cancer: A randomized controlled trial (PROGNOSIS-RCT).
Giger AW, Ditzel HM, Ditzel HJ, Ewertz M, Jørgensen TL, Pfeiffer P, Lund CM, Ryg J. Giger AW, et al. Among authors: ditzel hj. J Geriatr Oncol. 2024 Jan;15(1):101658. doi: 10.1016/j.jgo.2023.101658. Epub 2023 Nov 6. J Geriatr Oncol. 2024. PMID: 37939628 Free article. Clinical Trial.
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Karimi L, Alves CL, Terp MG, Tuttolomondo M, Portman N, Ehmsen S, Johansen LE, Bak M, Lim E, Ditzel HJ. Karimi L, et al. Among authors: ditzel hj. Cancer Commun (Lond). 2023 Jun;43(6):720-725. doi: 10.1002/cac2.12425. Epub 2023 Apr 26. Cancer Commun (Lond). 2023. PMID: 37101393 Free PMC article. No abstract available.
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.
Alves CL, Ditzel HJ. Alves CL, et al. Among authors: ditzel hj. Int J Mol Sci. 2023 Feb 24;24(5):4522. doi: 10.3390/ijms24054522. Int J Mol Sci. 2023. PMID: 36901954 Free PMC article. Review.
193 results